-
Mashup Score: 4Takeda’s Eohilia rebounds to win FDA approval as ‘first and only’ oral therapy for EoE - 2 month(s) ago
The FDA has approved Takeda Pharmaceuticals’ Eohilia as the “first and only oral therapy” for treatment of eosinophilic esophagitis in patients aged 11 years or older, according to a press release. The agency had denied Takeda’s new drug application for Eohilia (budesonide oral suspension) for this indication in 2021, citing only that it could “not be approved in
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 9Eosinophilic Esophagitis: 5 Things to Know - 2 month(s) ago
Although delayed diagnosis of EoE presents considerable risk to those with this chronic inflammatory disease, novel treatments are providing hope that a new era is on the horizon.
Source: www.medscape.comCategories: General Medicine News, Allergy-ImmunologyTweet
-
Mashup Score: 4Takeda’s Eohilia rebounds to win FDA approval as ‘first and only’ oral therapy for EoE - 2 month(s) ago
The FDA has approved Takeda Pharmaceuticals’ Eohilia as the “first and only oral therapy” for treatment of eosinophilic esophagitis in patients aged 11 years or older, according to a press release. The agency had denied Takeda’s new drug application for Eohilia (budesonide oral suspension) for this indication in 2021, citing only that it could “not be approved in
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 3AGA University - 4 month(s) ago
Friday, Dec. 8, 2023 12-1 p.m. ET Join us for this upcoming event in our Gastro Bites series — virtual webinars with leading experts. During the first portion of the session, we will discuss diet therapy and the choice between a step-up or step-down approach for treating eosinophilic esophagitis (EoE) patients. Register …
Source: agau.gastro.orgCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 16Global Incidence and Prevalence of Eosinophilic Esophagitis, 1976–2022: A Systematic Review and Meta-analysis - 5 month(s) ago
Owing to 2018 expanded diagnostic criteria for eosinophilic esophagitis (EoE) and thus a possible increase in diagnosis, previous studies on the global incidence and prevalence of EoE may need to be updated. We aimed to describe global, regional, and national trends in the incidence and prevalence of EoE from 1976 to 2022 and analyze their associations with geographic, demographic, and social factors through a systematic review.
Source: www.cghjournal.orgCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 3AGA University - 5 month(s) ago
Friday, Dec. 8, 2023 12-1 p.m. ET Join us for this upcoming event in our Gastro Bites series — virtual webinars with leading experts. During the first portion of the session, we will discuss diet therapy and the choice between a step-up or step-down approach for treating eosinophilic esophagitis (EoE) patients. Register …
Source: agau.gastro.orgCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 6Feeding Tube Placement, Complications, and Treatment... : Journal of Pediatric Gastroenterology and Nutrition - 5 month(s) ago
Methods: This was a retrospective cohort study of EoE patients at a large tertiary care health system. Demographics, clinical characteristics, and endoscopic findings were extracted from medical records, and patients who had a feeding tube were identified. Patients with and without a feeding tube were compared. Details about the tube, complications, and treatment were extracted. Growth, global symptomatic, endoscopic, and histopathologic (<15 eos/hpf) responses were compared before and after the initiation of feeding tube therapy. Results: We identified 39 of 1216 EoE patients who had a feeding tube (3%). Feeding tube patients were younger (mean age 6.3 years), reported more vomiting, and had a lower total endoscopic reference score than non-feeding tube patients (P < 0.01 for all). Tubes were used for therapy for an average of 6.8 years, with most patients (95%) receiving both pharmacologic and formula treatment for EoE. An emergency department visit for a tube complication was requir
Source: journals.lww.comCategories: General Medicine News, PediatricsTweet-
A study of feeding tube placement in pediatric patients with #EosinophilicEsophagitis: - Only a small percent of patients with EoE require tube feeding, mostly young children - Feeding tube therapy may improve growth, but clinical responses are variable https://t.co/MOkNjcU2Nw https://t.co/IcbBEXMLXQ
-
-
Mashup Score: 10Pooled Phase 2 and 3 Efficacy and Safety Data on Budesonide ... : Journal of Pediatric Gastroenterology and Nutrition - 5 month(s) ago
2.0 mg twice daily (b.i.d.) (phase 2, NCT01642212; phase 3, NCT02605837) in patients aged 11–17 years with EoE and dysphagia. Efficacy endpoints included histologic (≤6, ≤1, and <15 eosinophils per high-power field [eos/hpf]), dysphagia symptom (≥30% reduction in Dysphagia Symptom Questionnaire [DSQ] scores from baseline), and clinicopathologic (≤6 eos/hpf and ≥30% reduction in DSQ scores from baseline) responses at week 12. Change from baseline to week 12 in peak eosinophil counts, DSQ scores, EoE Histology Scoring System (EoEHSS) grade (severity) and stage (extent) total score ratios (TSRs), and total EoE Endoscopic Reference Scores (EREFS) were assessed. Safety outcomes were also examined. Results: Overall, 76 adolescents were included (BOS, n = 45; placebo, n = 31). Significantly more patients who received BOS than placebo achieved histologic responses (≤6 eos/hpf: 46.7% vs 6.5%; ≤1 eos/hpf: 42.2% vs 0.0%; <15 eos/hpf: 53.3% vs 9.7%; P < 0.001) and a clinicopathologic response (31.
Source: journals.lww.comCategories: General Medicine News, PediatricsTweet-
Phase 2/3 efficacy and safety data for Budesonide use in adolescents with #EosinophilicEsophagitis. A dose of 20mg BID associated with: - Improvements at week 12 compared to placebo - No association with new safety concerns compared to previous studies https://t.co/v5DiFDM4GR https://t.co/rkEuCB0J64
-
-
Mashup Score: 2AGA University - 5 month(s) ago
Friday, Dec. 8, 2023 12-1 p.m. ET Join us for this upcoming event in our Gastro Bites series — virtual webinars with leading experts. During the first portion of the session, we will discuss diet therapy and the choice between a step-up or step-down approach for treating eosinophilic esophagitis (EoE) patients. Register …
Source: agau.gastro.orgCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 4Eosinophilic Esophagitis (EoE) | AAAAI - 10 month(s) ago
The AAAAI offers articles written and reviewed by experts Eosinophilic Esophagitis (EoE).
Source: www.aaaai.orgCategories: Allergy-Immunology, Latest HeadlinesTweet
🚨BREAKING🚨 @US_FDA has approved @TakedaPharma's Eohilia as the “first and only oral therapy” for treatment of #eosinophilicesophagitis in patients aged 11 years or older, according to a press release. https://t.co/pUkVwSDTRZ